ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8% - Should You Buy?

Key Points

• Shares were up 8% mid-day to about $8.54 on Thursday on roughly 493,047 shares traded (a 66% drop versus average volume), and the stock remains below its 50‑day ($9.37) and 200‑day ($9.76) moving averages.
• Analysts are mixed: the consensus rating is Hold with a consensus target price of $29.33 (two Buys, one Hold, one Sell), while Leerink Partners set a $26 "outperform" target.
• Fundamentals show ongoing losses—reported EPS of $(0.42) matched estimates and analysts expect -0.55 EPS for the year, with a negative net margin (203.25%) and negative ROE—though revenue beat estimates ($28.09M); market cap is about $838M and institutional investors own ~68% of the stock.

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) were up 8% during mid-day trading on Thursday . The company traded as high as $8.70 and last traded at $8.5350. Approximately 493,047 shares traded hands during trading, a decline of 66% from the average daily volume of 1,452,389 shares. The stock had previously closed at $7.90.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Zacks Research raised shares of ARS Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 25th. Finally, Leerink Partners set a $26.00 target price on ARS Pharmaceuticals and gave the company an "outperform" rating in a report on Tuesday, March 10th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $29.33.

ARS Pharmaceuticals Stock Performance

The firm's fifty day moving average is $9.37 and its 200 day moving average is $9.76. The firm has a market capitalization of $838.09 million, a price-to-earnings ratio of -4.82 and a beta of 0.78. The company has a debt-to-equity ratio of 1.47, a current ratio of 7.28 and a quick ratio of 7.06.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Monday, March 9th. The company reported ($0.42) earnings per share for the quarter, meeting the consensus estimate of ($0.42). The firm had revenue of $28.09 million for the quarter, compared to analyst estimates of $25.58 million. ARS Pharmaceuticals had a negative net margin of 203.25% and a negative return on equity of 100.29%. On average, analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current fiscal year.

Institutional Trading of ARS Pharmaceuticals

A number of institutional investors have recently bought and sold shares of SPRY. Ameritas Investment Partners Inc. raised its stake in shares of ARS Pharmaceuticals by 16.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company's stock valued at $98,000 after acquiring an additional 777 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in ARS Pharmaceuticals by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company's stock worth $56,000 after purchasing an additional 982 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in ARS Pharmaceuticals by 3.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,994 shares of the company's stock worth $596,000 after purchasing an additional 1,234 shares during the period. ProShare Advisors LLC grew its holdings in ARS Pharmaceuticals by 11.3% during the fourth quarter. ProShare Advisors LLC now owns 15,139 shares of the company's stock valued at $176,000 after purchasing an additional 1,532 shares during the last quarter. Finally, Belpointe Asset Management LLC grew its holdings in ARS Pharmaceuticals by 8.9% during the third quarter. Belpointe Asset Management LLC now owns 18,860 shares of the company's stock valued at $190,000 after purchasing an additional 1,537 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.